Another failed drug trial may shift Exelixis' hopes to a buyout

Exelixis Inc.'s cancer-fighting drug Cometriq failed a late-stage trial in a type of prostate cancer, the company said Monday, pinning the once-high-flying biotech company's hopes on another study in kidney cancer and a partnership and possible buyout by Genentech Inc...